Intra-Cellular Therapies Inc. - Common Stock (ITCI)
131.24
-0.04 (-0.03%)
Intra-Cellular Therapeutics is a biopharmaceutical company focused on the development of innovative therapies for neuropsychiatric and neurological disorders
The company aims to address unmet medical needs by exploring the underlying mechanisms of cellular signaling and neurotransmission. Its research encompasses a range of conditions, including schizophrenia, mood disorders, and neurodegenerative diseases, leveraging advanced science and technology to create novel treatment options that have the potential to improve the quality of life for patients.
Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.
These 11 large-cap stocks saw significant growth last week, with notable news from companies such as Johnson & Johnson, MicroStrategy, and United Rentals.
The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rally
JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive
ITCI's flagship product, Caplyta, is a once-daily oral therapy approved for treating schizophrenia and depressive episodes linked to bipolar disorders, which reportedly raked in sales of $464 million in 2023.
Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline.
Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk reduction and favorable safety profile.
